Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)
Status:
Completed
Trial end date:
2014-12-31
Target enrollment:
Participant gender:
Summary
AC220 will be administered as a once daily oral solution given continuously as 28-day
treatment cycles, without any rest periods, until disease progression, relapse, intolerance
to the drug, or elective allogeneic hematopoietic stem cell transplantation (HSCT).